MyoStrain's Economic Benefits in the Diagnosis and Management of Heart Failure Detailed in New Health Economics Review
MORRISVILLE, N.C., June 19, 2019 – A new article demonstrating the significant cost savings that could be achieved using MyoStrain® to detect and manage early heart failure was published in Health Economics Review. The article, authored by Avalon Health Economics (Avalon), compares MyoStrain to Echocardiography (ECHO), the most widely-used diagnostic method for heart function. Avalon developed a cost impact model from both a ‘payer perspective’ and a ‘hospital perspective’ to compare the use of MyoStrain versus Echo to diagnose and manage early-stage heart failure. In the models, MyoStrain showed cost-dominance over Echo from both payer and hospital perspective.
The link to the article is provided below:
Citation: Schneider JE, et al. Economic Evaluation of Cardiac Magnetic Resonance with Fast-SENC in the Diagnosis and Management of Early Heart Failure. Health Economics Review. 2019 May;9(1):13. Doi:10.1186/s13561-019-0229-7.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain® has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.